- Provider
- Hers
- Medication format
- Wegovy tablets
- Medication starting offer
- From $149 per month; terms and dose matter
- Required membership
- $39 first month, then $149 per month
A pill is a different formulation
Hers currently offers Wegovy pill through its weight-loss service. Wegovy tablets are an approved oral semaglutide product with formulation-specific directions. They are not a compounded semaglutide pill or a weekly injection in another container.[source][source]
The practical format may matter to a reader, but convenience should be assessed using the actual instructions and medical history.
Do not apply the injection trial directly
SURMOUNT-5 compared weekly subcutaneous medications. Its semaglutide result does not establish a head-to-head oral-Wegovy outcome against tirzepatide.[source]
Evidence from another oral-product trial also needs its own population, dose and analysis attached. We do not turn unrelated study averages into a direct comparison.
The headline medication quote excludes membership
Hers advertises a starting medication price from $149 per month, with selected dose and program terms to confirm. Membership is required and separately billed at $39 initially, then $149 per month.[source]
The ongoing complete bill is therefore not the medication headline alone. Obtain the selected-dose quote and next renewal amount before budgeting.
Understand the consequences of ending membership
The product page says canceling the care membership also cancels the active medication plan and access to platform care. Discuss how ongoing treatment would be managed if changing services.
This review does not advise a medication stop, restart or conversion. Current labeling and the prescribing professional should guide any treatment change.[source]
Evaluate the oral format on its own terms
This option is relevant for someone discussing an approved oral treatment with a clinician and considering Hers’ support model. Compare its daily regimen, complete cost and continuity plan with the actual alternatives, rather than assuming a pill removes every practical tradeoff.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- Hers: Wegovy pillCurrent product page and starting medication quote · Checked October 8, 2026
- Wegovy prescribing informationManufacturer labeling; formulation-specific directions and safety information · Checked October 8, 2026
- Aronne et al., NEJM 2025: tirzepatide compared with semaglutide for obesityPrimary randomized trial abstract; SURMOUNT-5, 751 adults without diabetes, 72 weeks; funded by Eli Lilly · Checked October 8, 2026